These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29060621)

  • 1. Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.
    Li MH; Mestre TA; Fox SH; Taati B
    Annu Int Conf IEEE Eng Med Biol Soc; 2017 Jul; 2017():3377-3380. PubMed ID: 29060621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
    Li MH; Mestre TA; Fox SH; Taati B
    Parkinsonism Relat Disord; 2018 Aug; 53():42-45. PubMed ID: 29748112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning.
    Loo RTJ; Tsurkalenko O; Klucken J; Mangone G; Khoury F; Vidailhet M; Corvol JC; Krüger R; Glaab E;
    Parkinsonism Relat Disord; 2024 Sep; 126():107054. PubMed ID: 38991633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology.
    Mera TO; Burack MA; Giuffrida JP
    Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():154-7. PubMed ID: 23365855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
    Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
    Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
    Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
    J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
    Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebellar stimulation prevents Levodopa-induced dyskinesia in mice and normalizes activity in a motor network.
    Coutant B; Frontera JL; Perrin E; Combes A; Tarpin T; Menardy F; Mailhes-Hamon C; Perez S; Degos B; Venance L; Léna C; Popa D
    Nat Commun; 2022 Jun; 13(1):3211. PubMed ID: 35680891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks.
    Keijsers NL; Horstink MW; van Hilten JJ; Hoff JI; Gielen CC
    Mov Disord; 2000 Nov; 15(6):1104-11. PubMed ID: 11104192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.
    Delamarre A; Tison F; Li Q; Galitzky M; Rascol O; Bezard E; Meissner WG
    J Neural Transm (Vienna); 2019 Jun; 126(6):789-793. PubMed ID: 31098725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noradrenergic drugs for levodopa-induced dyskinesia.
    Colosimo C; Craus A
    Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
    Tran TN; Vo TNN; Frei K; Truong DD
    J Neural Transm (Vienna); 2018 Aug; 125(8):1109-1117. PubMed ID: 29971495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebellar connectivity in Parkinson's disease with levodopa-induced dyskinesia.
    Yoo HS; Choi YH; Chung SJ; Lee YH; Ye BS; Sohn YH; Lee JM; Lee PH
    Ann Clin Transl Neurol; 2019 Nov; 6(11):2251-2260. PubMed ID: 31643140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC; Pahwa R; Mallya U
    J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.